U.S. Markets closed

Nevro (NVRO) Gains Ground on Solid Preliminary Q4 Results

Zacks Equity Research

Nevro Corp. NVRO announced preliminary results for fourth-quarter and full-year 2019 on Jan 14.

Notably, full-year worldwide revenues are expected to total $390.3 million that suggests a rise of 0.8% from 2018 figures. The Zacks Consensus Estimate for the metric is pegged at $385.1 million.

For the fourth quarter, worldwide revenues are projected at $114.4 million, which calls for a rise of 6% from $107.9 million in the year-ago quarter.

The company expects to release fourth-quarter 2019 results in February.

Content Investors

Nevro’s preliminary results have boosted investors’ optimism. Post the preliminary release, shares of this Zacks Rank #3 (Hold) company have climbed 3.5% to $118.27 at close on Jan 15.

Also, in the past three months, the stock has gained 38.5% compared with the industry’s 11.7% growth. The S&P 500 Index is up 9.7% in the same time frame.

Quarterly Projections

U.S. revenues are estimated to total $97.9 million, which indicates an increase of 6.9% from the prior-year quarter’s level. International revenues are projected to be $16.5 million, suggesting a rise of 1.2% from the year-ago quarter’s figure.

Revenues from U.S. trial procedure grew 17% and the same from permanent implant procedure rose 20%.

Full-Year Projections

U.S. revenues are expected to amount to $326 million, which calls for a rise of 1.3% from $321.8 million in 2018. International revenues are projected at $64.3 million, indicating a decline of 1.8% from the year-ago tally.

2020 Worldwide Revenue Outlook

Nevro currently expects full-year worldwide revenues in the range of $435-$440 million.

Summing Up

Nevro is anticipated to have delivered solid fourth-quarter and full-year performances. Notably, the company’s top line is projected to beat the consensus mark for 2019.

An upbeat 2020 worldwide revenue outlook buoys optimism in the stock.

Key Picks

Some better-ranked stocks in the broader medical space are Cerner Corporation CERN, DexCom, Inc. DXCM and HealthEquity, Inc. HQY. While HealthEquity sports a Zacks Rank #1 (Strong Buy), Cerner and DexCom carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Cerner’s long-term earnings growth rate is estimated at 13.6%.

DexCom’s fourth-quarter earnings growth rate is projected at 31.5%.

HealthEquity’s long-term earnings growth rate is pegged at 25%.

Free: Zacks’ Single Best Stock Set to Double

Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.

This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.

See 5 Stocks Set to Double>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Cerner Corporation (CERN) : Free Stock Analysis Report
Nevro Corp. (NVRO) : Free Stock Analysis Report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
HealthEquity, Inc. (HQY) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research